Neuphoria Therapeutics (NEUP) 10-Q 14 Nov 24 2025 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Sep. 30, 2024	Oct. 31, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Amendment Flag	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	Q1
Entity Registrant Name	BIONOMICS LIMITED/FI
Entity Central Index Key	0001191070
Securities Act File Number	001-41157
Entity Tax Identification Number	00-0000000
Entity Incorporation, State or Country Code	C3
Current Fiscal Year End Date	--06-30
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Bankruptcy Proceedings, Reporting Current	true
Entity Address, Address Line One	200 Greenhill Road
Entity Address, City or Town	Eastwood, SA
Entity Address, Country	AU
Entity Address, Postal Zip Code	5063
City Area Code	+61
Local Phone Number	8 8150 7400
Title of 12(b) Security	American Depositary Shares
Trading Symbol	BNOX
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		3,514,922,864

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2024	Jun. 30, 2024
Current assets:
Cash and cash equivalents	$ 8,082,410	$ 12,608,109
Accounts receivable, non-trade	115,960	126,884
Prepaid insurance expense	231,108	458,765
Total current assets	8,429,478	13,193,758
Property and equipment, net	1,964	1,994
Intangible assets, net	5,301,839	5,467,522
Operating lease right-of-use assets	197,447	216,975
Restricted cash	82,491	78,826
Goodwill	8,903,988	8,690,018
Total assets	22,917,207	27,649,093
Current liabilities:
Accounts payable	1,325,994	2,243,662
Accrued expenses and other current liabilities	1,095,838	1,463,421
Operating lease liability	129,881	121,990
Total current liabilities	2,551,713	3,829,073
Operating lease liability, net of current portion	89,469	117,628
Contingent consideration	679,313	587,762
Deferred tax liability	831,324	963,540
Accompanying warrants liability	1,691,587	4,657,832
Other non-current liabilities	3,437	2,886
Total liabilities	5,846,843	10,158,721
Commitments and contingencies (Note 16)
Shareholders’ equity:
Ordinary shares, no par value; 3,117,662,864 and 2,384,539,964 shares issued and outstanding at September 30, 2024 and June 30, 2024, respectively
Additional paid in capital	198,280,436	198,481,038
Accumulated other comprehensive loss, net of tax	(2,428,214)	(3,013,595)
Accumulated deficit	(178,781,858)	(177,977,071)
Total shareholders’ equity	17,070,364	17,490,372
Total liabilities and shareholders’ equity	$ 22,917,207	$ 27,649,093

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2024	Jun. 30, 2024
Statement of Financial Position [Abstract]
Ordinary shares, no par value (in Dollars per share)
Ordinary shares, shares issued	3,117,662,864	2,384,539,964
Ordinary shares, shares outstanding	3,117,662,864	2,384,539,964

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Operating expenses:
Research and development	$ 1,900,903	$ 3,088,229
General and administrative	1,666,824	2,379,378
Total operating expenses	3,567,727	5,467,607
Loss from operations	(3,567,727)	(5,467,607)
Other income (loss):
Interest income, net	36,096	86,439
(Loss) gain on foreign currency transactions	(280,037)	(1,635)
Gain (loss) on fair value adjustments	2,874,694	(124,558)
Total other income (loss)	2,630,753	(39,754)
Loss before income tax expense	(936,974)	(5,507,361)
Income tax benefit	132,187	34,793
Net loss	(804,787)	(5,472,568)
Other comprehensive loss:
Unrealized gain (loss) on foreign currency translation	585,381	(63,469)
Total other comprehensive loss:	585,381	(63,469)
Comprehensive loss	$ (219,406)	$ (5,536,037)
Net loss per share -basic	$ 0	$ 0
Net loss per share -diluted	$ 0	$ 0
Weighted-average common shares outstanding -basic	2,808,140,743	1,495,995,035
Weighted-average common shares outstanding -diluted	2,808,140,743	1,495,995,035

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Changes in Shareholders' Equity (Unaudited) - USD ($)	Total	Ordinary Shares	Stock Subscription Receivable	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Balance at Jun. 30, 2023	$ 22,010,563			$ 187,554,251	$ (3,058,783)	$ (162,484,905)
Balance (in Shares) at Jun. 30, 2023		1,468,735,424
Issuance of ADS shares, net of issuance costs	612,538		$ (5,648,976)	6,261,514
Issuance of ADS shares, net of issuance costs (in Shares)		378,155,880
Share-based compensation	140,448			140,448
Other comprehensive income (loss)	(63,469)				(63,469)
Net loss	(5,472,568)					(5,472,568)
Balance at Sep. 30, 2023	17,227,512		$ (5,648,976)	193,956,213	(3,122,252)	(167,957,473)
Balance (in Shares) at Sep. 30, 2023		1,846,891,304
Balance at Jun. 30, 2023	22,010,563			187,554,251	(3,058,783)	(162,484,905)
Balance (in Shares) at Jun. 30, 2023		1,468,735,424
Net loss	(15,500,000)
Balance at Jun. 30, 2024	17,490,372			198,481,038	(3,013,595)	(177,977,071)
Balance (in Shares) at Jun. 30, 2024		2,384,539,964
Exercise of pre-funded ADS warrants	409			409
Exercise of pre-funded ADS warrants (in Shares)		733,122,900
Share issue costs	(227,747)			(227,747)
Share-based compensation	26,736			26,736
Other comprehensive income (loss)	585,381				585,381
Net loss	(804,787)					(804,787)
Balance at Sep. 30, 2024	$ 17,070,364			$ 198,280,436	$ (2,428,214)	$ (178,781,858)
Balance (in Shares) at Sep. 30, 2024		3,117,662,864

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Changes in Shareholders' Equity (Unaudited) (Parentheticals) - USD ($)	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Statement of Stockholders' Equity [Abstract]
Net of issuance costs	$ 227,747	$ 500,000

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024
Cash flows from operating activities:
Net loss	$ (804,787)	$ (5,472,568)	$ (15,500,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	26,736	132,739
Depreciation and amortization expense	165,713	165,909
Non-cash rent expense	19,528	36,166
Change in fair value of accompanying warrant liability	(2,966,245)
Change in fair value of contingent consideration	91,551	124,558
Effect of foreign currency remeasurement	233,044	67,319
Changes in assets and liabilities:
Accounts receivable, non-trade	10,924	(16,252)
Prepaid insurance expense	227,657	427,316
Accounts payable	(917,668)	880,613
Accrued expenses and other current liabilities	(367,583)	(704,745)
Operating lease liabilities	(20,268)	(36,393)
Deferred tax liability	(132,216)	(34,793)
Other non-current liabilities	551	331
Net cash used in operating activities	(4,433,063)	(4,429,800)
Cash flows from financing activities:
Issue costs associated with ADS shares and ADS pre-funded warrants	(227,747)	(500,000)
Proceeds from the exercise of pre-funded ADS warrants	409	0
Proceeds from the sale of ADS shares, net	0	6,261,514
Stock issued pursuant to a subscription receivable	0	(5,648,976)
Net cash (used in) provided by financing activities	(227,338)	612,538
Effect of exchange rate on changes on cash, cash equivalents, and restricted cash	138,367	(152,773)
Net decrease in cash, cash equivalents, and restricted cash	(4,660,401)	(3,817,262)
Cash, cash equivalents, and restricted cash, beginning of period	12,686,935	12,181,944	12,181,944
Cash, cash equivalents, and restricted cash, end of period	8,164,901	8,211,909	12,686,935
Reconciliation of cash, cash equivalents, and restricted cash:
Cash and cash equivalents	8,082,410	8,135,059	12,608,109
Restricted cash	82,491	76,850
Total cash, cash equivalents, and restricted cash	$ 8,164,901	$ 8,211,909	$ 12,686,935

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024
Pay vs Performance Disclosure
Net Income (Loss)	$ (804,787)	$ (5,472,568)	$ (15,500,000)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

The Company and Basis of Presen

The Company and Basis of Presentation	3 Months Ended
	Sep. 30, 2024
The Company and Basis of Presentation [Abstract]
The Company and Basis of Presentation	Note 1. The Company and Basis of Presentation Bionomics Limited (“the Company”) is a public company incorporated in Australia. The principal activities of the Company and its controlled entities during the period include the development of novel drug candidates focused on the treatment of serious central nervous system disorders. Details of the Company’s entity structure at the end of the reporting period are as follows: Name Entity Country of Incorporation Bionomics Limited Parent Australia Bionomics, Inc. Subsidiary United States Liquidity and Going Concern As of September 30, 2024 , the Company had working capital of $ 5.9 million, an accumulated deficit of $ 178.8 million, and cash and cash equivalents of $ 8.1 million. The Company has not generated any product revenues and has not achieved profitable operations. There is no assurance that profitable operations will ever be achieved, and, if achieved, could be sustained on a continuing basis. In addition, development activities, clinical and non-clinical testing, and commercialization of the Company’s products will require significant additional financing. The Company is subject to a number of risks similar to other life science companies, including, but not limited to, risks related to the successful discovery, development, and commercialization of product candidates, raising additional capital, development of competing drugs and therapies, protection of proprietary technology, and market acceptance of the Company’s products. As a result of these and other factors and the related uncertainties, there can be no assurance of the Company’s future success. In accordance with ASC 205-40, Going Concern , the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued. The Company incurred net losses of $ 0.8 million for the three months ended September 30, 2024 and $ 15.5 million for the year ended June 30, 2024. The Company also used $ 4.4 million of cash for operating activities during the three months ended September 30, 2024. Based upon the Company’s current operating plans, the Company believes that its existing cash and cash equivalents, combined with its existing ATM facility, will be sufficient to continue funding its development activities into late in the first quarter of fiscal year 2026, which is less than twelve months from the date these condensed consolidated financial statements are issued. Accordingly, based on its recurring losses from operations incurred since inception, the expectation of continued operating losses, and the need to raise additional capital to finance its future operations, the Company determined that there is substantial doubt about the Company’s ability to continue as a going concern within twelve months of the issuance date of these financial statements. The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty and assumes the Company will continue as a going concern through the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. The Company plans to address this condition through the sale of ordinary shares in public offerings and/or private placements, debt financings, or through other capital sources, including collaborations with other companies or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all, nor is it considered probable under the accounting standards. If the Company is unable to obtain sufficient funding on acceptable terms, it could be forced to delay, reduce or eliminate some or all its research and development programs or commercialization activities, which could materially adversely affect its business prospects or its ability to continue operations. Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the U.S. (“U.S. GAAP” or “GAAP”) and include the accounts of our wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The condensed consolidated balance sheet as of June 30, 2024 was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. The accompanying condensed consolidated financial statements, as of September 30, 2024 and for the three months ended September 30, 2024, are unaudited and have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto for the year ended June 30, 2024 included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2024 filed with the SEC on September 30, 2024. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, as necessary for the fair statement of the Company’s financial position as of September 30, 2024, results of its operations for the three months ended September 30, 2024, stockholders’ equity for the three months ended September 30, 2024, and cash flows for the three months ended September 30, 2024, have been made. The results of operations for the three months ended September 30, 2024 are not necessarily indicative of the results of operations to be expected for the year ending June 30, 2025. The Company has historically been classified as a foreign private issuer (“FPI”). However, as of December 31, 2023, the Company determined that it no longer satisfied the criteria to be considered an FPI. As such, beginning on July 1, 2024, the Company was required to begin utilizing the SEC’s domestic reporting forms and apply U.S. GAAP as its accounting framework. There were no material adjustments required as a result of this adjustment to retrospectively apply U.S. GAAP to the accompanying condensed consolidated financial statements. Another requirement of utilizing the SEC’s domestic reporting forms is a requirement to use the U.S. dollar as the reporting currency. These consolidated financial statements reflect the change in reporting currency to the U.S. dollar applied retrospectively. References to “$” are U.S dollars and references to “A$” are to Australian dollars. The presentation of shareholders' equity in the consolidated balance sheets at June 30, 2023, as previously reported under International Financial Reporting Standards ("IFRS") was reclassified to comply with the presentation under U.S. GAAP. The ordinary shares have no par under Australian law. The Company has elected a policy to present all proceeds from ordinary shares within additional paid-in capital.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2024
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Use of Estimates The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosure of revenue, expenses, and certain assets and liabilities at the balance sheet date. Such estimates include the performance obligations under the Company’s collaboration agreements, the collectability of receivables, impairment evaluation for goodwill and intangible assets, and the fair values of contingent consideration and warrants. Actual results may differ from such estimates. Summary of Significant Accounting Policies There were no changes to significant accounting policies during the three months ended September 30, 2024 , as compared to those identified in the fiscal 2024 Annual Report.

Fair Value Measurement

Fair Value Measurement	9 Months Ended
	Sep. 30, 2024
Fair Value Measurement [Abstract]
Fair Value Measurement	Note 3. Fair Value Measurement The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The following tables set forth the fair value of the Company’s liabilities at fair value on a recurring basis based on the three-tier fair value hierarchy: September 30, 2024 Level 1 Level 2 Level 3 Total Liabilities: Contingent consideration $ - $ - $ 679,313 $ 679,313 Accompanying warrants liability - - 1,691,587 1,691,587 Total liabilities measured at fair value $ - $ - $ 2,370,900 $ 2,370,900 June 30, 2024 Level 1 Level 2 Level 3 Total Liabilities: Contingent consideration $ - $ - $ 587,762 $ 587,762 Accompanying warrants liability - - 4,657,832 4,657,832 Total liabilities measured at fair value $ - $ - $ 5,245,594 $ 5,245,594 The Company has no financial assets that are measured at fair value. The liabilities measured at fair value at September 30, 2024 and June 30, 2024 are contingent consideration and the accompanying warrant liability. The value of financial assets and other financial liabilities approximate their fair value. The following table gives information about how the fair value of the financial liability is determined. The accompanying warrants liability relates to the Company’s issuance of accompanying warrants in conjunction with a Private Placement in June 2024. The fair value of the accompanying warrants liability was based on valuations that required inputs that were both significant to the fair value measurement and unobservable. This approach resulted in a classification of the accompanying warrants liability as Level 3 of the fair value hierarchy. The following table summarizes changes in the fair value of the contingent consideration and the accompanying warrants liability, each for which each fair value was determined by Level 3 inputs: Contingent Freestanding Balance at June 30, 2024 $ 587,762 $ 4,657,832 Change in fair value 91,551 ( 2,966,245 ) Balance at September 30, 2024 $ 679,313 $ 1,691,587 Contingent Balance at June 30, 2023 $ 2,456,199 Change in fair value ( 124,558 ) Balance at September 30, 2023 $ 2,331,641 The Company evaluates transfers between levels at the end of each reporting period. There were no transfers between levels during the periods presented.

Accounts Receivable, Non-trade

Accounts Receivable, Non-trade	3 Months Ended
	Sep. 30, 2024
Accounts Receivable, Non-trade [Abstract]
Accounts Receivable, Non-trade	Note 4. Accounts Receivable, Non-trade Accounts receivable, non-trade consist of the following: September 30, June 30, 2024 2024 Research and development incentives receivable $ 100,625 $ 96,154 GST receivables 14,059 30,444 Interest receivable 1,276 286 Total accounts receivable, non-trade $ 115,960 $ 126,884

Leases

Leases	3 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Leases	Note 5. Leases In June 2021, the Company entered into a 5-year lease agreement (the “Greenhill Lease”) for its Australian facility located in Dulwich, South Australia. The initial term of the lease expires in May 2026. The Greenhill Lease requires monthly lease payments that are subject to annual increases of 3 % throughout the lease term. The lease also includes two renewal options, at the election of the Company, to renew or extend the lease for additional terms of one year each. These optional periods have not been considered in the determination of the right-of-use assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options. Variable lease expense for the premises primarily consists of common area maintenance and other operating costs. The following table summarizes the Company’s recognition of the Greenhill Lease including the remaining lease payments through the end of the expected lease term: September 30, 2024 Remainder of 2025 $ 145,186 2026 182,584 Remaining lease payments 327,770 Less: effect of discounting ( 108,420 ) Present value of lease liability $ 219,350 Current operating lease liabilities $ 129,881 Non-current operating lease liabilities 89,469 Total $ 219,350 The discount rate associated with the Company’s operating lease is 3.5 % and the weighted average remaining lease term is approximately 1.8 years. The following table summarizes the effect of lease costs in the Company’s condensed consolidated statements of operations and other comprehensive income (loss): Three months ended September 30, 2024 2023 Operating lease costs Research and development $ 14,313 $ 13,996 General and administrative 16,121 15,724 Total $ 30,434 $ 29,720

Goodwill

Goodwill	3 Months Ended
	Sep. 30, 2024
Goodwill [Abstract]
Goodwill	Note 6. Goodwill The following table summarizes changes in the carrying value of goodwill for the three months ended September 30, 2024 and 2023: Carrying amount at June 30, 2024 $ 8,690,018 Foreign currency exchange differences 213,970 Carrying amount at September 30, 2024 $ 8,903,988 Carrying amount at June 30, 2023 $ 8,694,186 Foreign currency exchange differences ( 119,490 ) Carrying amount at September 30, 2023 $ 8,574,696 The Company reviews goodwill for impairment at the reporting unit on an annual basis during the fourth quarter, and when events or changes in circumstances indicate that a reduction in the carrying value may not be recoverable. The reporting unit has been identified as the drug development business unit. There were no impairment indicators identified by the Company at September 30, 2024.

Intangible Assets

Intangible Assets	3 Months Ended
	Sep. 30, 2024
Intangible Assets [Abstract]
Intangible Assets	Note 7. Intangible Assets Intellectual Property The acquired intellectual property relates to cancer stem cell technology, and is carried at its cost as at its date of acquisition, less accumulated amortization. Cancer Stem Carrying amount at June 30, 2024 $ 5,467,522 Amortization expense ( 165,683 ) Carrying amount at September 30, 2024 $ 5,301,839 Carrying amount at June 30, 2023 $ 6,130,253 Amortization expense ( 165,683 ) Carrying amount at September 30, 2023 $ 5,964,570 Acquired intellectual property with a finite life is recognized as an asset at cost and amortized on a straight line basis over its estimated useful life of 20 years. There is currently no internally generated intellectual property that has been capitalized.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Sep. 30, 2024
Accrued Expenses and Other Current Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	Note 8. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consist of the following: September 30, June 30, 2024 2024 Salary and benefits $ 719,235 $ 648,858 Insurance 78,649 311,172 Professional and consulting fees 229,988 297,780 Research and development expenses - 134,910 EDA Loan 34,660 33,120 Other 33,306 37,581 Total accrued expenses and other current liabilities $ 1,095,838 $ 1,463,421

Share Based Compensation

Share Based Compensation	3 Months Ended
	Sep. 30, 2024
Share Based Compensation [Abstract]
Share Based Compensation	Note 9. Share Based Compensation Equity awards for executives and employees have been and are provided by a combination of equity plans that may include the: • Employee Share Plan (the “A$ 1,000 Plan”); • Employee Share Option Plan (“ESOP”); and • Employee Equity Plan (“EEP”). Participation in these plans is at our board of directors’ discretion and no individual has an ongoing contractual right to participate in a plan or to receive any guaranteed benefits. For key appointments, an initial allocation of equity may be offered as a component of their initial employment agreement. The structure of equity awards is under the active review of the Nomination and Remuneration Committee to ensure it meets good corporate practice for a company of our size, nature and company lifecycle. The following describes the material terms of each of the plans. Employee Share Plan The objective of the A$ 1,000 Plan is to assist Management in the attraction and retention of employees, and to provide encouragement to become shareholders. An annual allocation of up to A$ 1,000 of shares may be granted and taxed on a concessional basis. No shares were issued to employees under the A$ 1,000 Plan during the three months ended September 30 2024 and 2023, respectively. The Bionomics Employee Equity Plan and Bionomics Employee Share Option Plan The EEP replaced the ESOP at the Annual General Meeting held December 2, 2021. The EEP was last amended on October 31, 2021 to provide the Company with increased flexibility to settle EEP awards offered or granted to non-Australian employees and directors by enabling it to offer and grant EEP awards that may be settled in American Depository Shares (“ADS”) (at a number of ADS’ that represents the appropriate number of Ordinary Shares offered or granted under the award). In addition, the amendment permits the Company to (i) determine any monetary amounts and accept payments related to the EEP or awards issued thereunder in United States dollars (or any other currency the Board deems acceptable), (ii) impose terms and conditions on the EEP or awards issued thereunder to comply with the securities and tax laws of the United States (or any other jurisdiction the Board deems appropriate), and (iii) take any other steps the Board deems necessary or desirable to settle EEP awards in ADSs. Share-based compensation benefits have been provided to employees via the Employee Equity Plan, with the exception of share options issued to the Executive Chairman and the Chief Executive Officer which were each approved by shareholders at the General Meeting held in February 2023. Staff eligible to participate in the plan are those who have been a full-time or part-time employee of the Company for a period of not less than six months or are members of the Board of Directors. Options are granted under the plan for no consideration and vest equally over five years , or when vesting conditions are achieved, unless they are bonus options which vest immediately. The amounts disclosed as remuneration relating to options are the assessed fair values at grant date of those options allocated equally over the period from grant date to vesting date. The following table summarizes employee and non-employee share option activity for the three months ended September 30, 2024: Number Weighted Weighted Aggregate (in years) Outstanding as of June 30, 2024 110,449,330 A$ 0.12 4.18 - Lapsed ( 13,015,000 ) A$ 0.01 Outstanding as of September 30, 2024 97,434,330 A$ 0.13 4.74 - Options exercisable as of September 30, 2024 79,909,138 A$ 0.16 5.29 - As of September 30, 2024, there was less than $ 0.1 million of unrecognized compensation cost related to unvested employee share option awards outstanding, which is expected to be recognized as expense over a weighted average period of 1.2 years. In determining the fair value of the share-based awards, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine. During the three months ended September 30, 2024 and 2023, the Company recognized total share-based compensation expense of less than $ 0.1 million and $ 0.1 million, respectively, substantially all of which was recorded as general and administrative expense in each period. There were no equity awards issued during the three months ended September 30, 2024 or 2023, respectively.

Warrants

Warrants	3 Months Ended
	Sep. 30, 2024
Warrants [Abstract]
Warrants	Note 10. Warrants The following table summarizes warrant activity for the three months ended September 30, 2024: Number of (1) Weighted Balance at June 30, 2024 18,932,477 $ 0.66 Exercised ( 4,072,905 ) $ - Balance at September 30, 2024 14,859,572 $ 0.84 (1) Each ADS warrant converts into ordinary shares at a conversion ratio of 1:180 . The classification, expiration date, and exercise price of individual warrants at September 30, 2024 are as follows: Number of Exercise Price Expiration Date Classification 2024 pre-funded ADS warrants 2,207,000 $ 0.0001 No expiry Equity 2024 accompanying ADS warrants 12,652,572 $ 0.99 June 2029 Liability 14,859,572 ADS warrants were vested and exercisable at September 30, 2024. The pre-funded ADS warrants have no expiry associated with them. The weighted average remaining contractual life of the accompanying ADS warrants outstanding at September 30, 2024 is 4.68 years.

Ordinary Shares

Ordinary Shares	3 Months Ended
	Sep. 30, 2024
Stockholders' Equity Note [Abstract]
Ordinary shares	Note 11. Ordinary shares During the three months ending September 30, 2023, the Company issued 2,100,866 ADS', representing 378,155,880 ordinary shares, for gross proceeds of $ 6,7 million net of issuance costs of $ 0.5 million. 1,508,727 of the ADS's were issued subject to a subscription agreement which settled on October 3, 2023 when the Company received the remaining $ 5.6 million.

Income Taxes

Income Taxes	3 Months Ended
	Sep. 30, 2024
Income Taxes [Abstract]
Income Taxes	Note 12. Income Taxes For interim financial reporting, the Company estimates its annual effective tax rate ("ETR") based on the projected income for its entire fiscal year and records a provision or benefit for income taxes quarterly, based on the estimated annual effective income tax rate. Our ETR from continuing operations was 14.1 % for the three months ended September 30, 2024 and 0.6 % for the three months ended September 30, 2023. The Company recognized a tax benefit of $ 132,187 for the period ending September 30, 2024 and a tax benefit of $ 34,793 for the period ending September 30, 2023.

Loss per Share

Loss per Share	3 Months Ended
	Sep. 30, 2024
Loss per Share [Abstract]
Loss per Share	Note 13. Loss per Share The following potential ordinary shares are anti-dilutive and are therefore excluded from the weighted average number of ordinary shares for the purposes of diluted loss per share. September 30, 2024 2023 Options to purchase common stock 97,434,330 117,196,315 Warrants to purchase common stock 14,859,572 —

Related Party Transactions

Related Party Transactions	3 Months Ended
	Sep. 30, 2024
Related Party Transactions [Abstract]
Related Party Transactions	Note 14. Related Party Transactions Danforth Advisors In July 2021, we entered into a consulting agreement with Danforth Advisors LLC (“Danforth”) to provide consulting services to the Company. The Danforth agreement was amended in May 2023, and further amended in August 2023. Pursuant to the agreement, Danforth provides us with the Chief Financial Officer services of Mr. Cunningham in exchange for fees payable to Danforth. The Danforth agreement will continue until such time as either party to it has given notice of termination pursuant thereto with cause upon 30 days prior written notice to the other party; or without cause upon 60 days prior written notice. WG Partners LLP In December 2023, we entered into an engagement letter with WG Partners LLP to provide financial advisory services to Bionomics. David Wilson, a director of Bionomics, is the Chairman and Chief Executive Officer of WG Partners. Under the agreement, Bionomics must pay to WG Partners a monthly fee of $ 15,000 and commission of up to 5 % of any fundraising proceeds attributable to this relationship. The agreement will continue until such time as a party gives 30 days prior written notice of termination to the other party. During the three-month period ended September 30, 2024, Bionomics paid WG Partners $ 59,841 for its services under terms and conditions that are on an arms-length basis.

Contingent Consideration

Contingent Consideration	3 Months Ended
	Sep. 30, 2024
Contingent Consideration [Abstract]
Contingent Consideration	Note 15. Contingent Consideration As a result of the acquisition of Eclipse Therapeutic, Inc (“Eclipse”) during the year ended June 30, 2013, the Company determines and recognizes at each reporting date the fair value of the additional consideration that may be payable to Eclipse security holders due to potential royalty payments based on achieving late-stage development success or partnering outcomes based on Eclipse assets. Such potential earn-out payments are recorded at fair value and include several significant estimates including adjusted revenue projections and expenses, probability of such projections, and a suitable discount rate to calculate fair value. Due to changes in the projected inputs associated with the timing and quantum of expected cash outflows, which are in USD dollars, the liability increased by approximately $ 0.1 million during the three months ended September 30, 2024. Inputs used are based on the anticipated amounts and timing of potential milestone and royalty payments from licensing agreement with Carina Biotech Pty Ltd (“Carina”). The guidance in ASC 805, Business Combinations , requires an acquirer to recognize contingent consideration obligations as of the acquisition date at fair value as part of the consideration transferred in exchange for the acquired business. Subsequent changes in the fair value are recognized in the Condensed Consolidated Statement of Operations and Comprehensive Loss (see Note 3).

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Sep. 30, 2024
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 16. Commitments and Contingencies Ironwood Pharmaceuticals, Inc. In January 2012, the Company entered into a research and license agreement with Ironwood Pharmaceuticals, Inc. (“Ironwood”) pursuant to which Ironwood was granted worldwide development and commercialization rights for BNC210. In November 2014, the parties mutually agreed to terminate this license agreement, reverting all rights to BNC210 back to the Company. The sole obligation to Ironwood is to pay Ironwood low to mid-single digit royalties on the net sales of BNC210, if commercialized. It is not practicable to estimate the future payments of any such royalties that may arise due to the stage of development of BNC210. Severance Obligation The Company has a contingent liability in relation to the employment agreement with Dr. Spyros Papapetropoulos for severance pay of $ 787,500 . Depositary Agreement with Citibank As a result of the Company planning to affect a redomiciliation by a scheme of arrangement under Part 5.1 of the Australian Corporations Act which would change the jurisdiction of the holding company of the Bionomics Group from Australia to the United States, we will terminate the ADR Depositary Agreement with Citibank. We may be required to pay significant additional fees for the withdrawal or termination of this program and are not able to estimate what those fees will be.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	Note 17. Subsequent Events The Company has evaluated subsequent events through November 14, 2024 and has concluded that no events or transactions have occurred that require disclosure in the accompanying consolidated financial statements, except as follows: On October 24, 2024, in connection with the Company’s June 4, 2024 private placement offering of ADS’, pre-funded warrants and an accompanying warrants (the “June 2024 Offering”), Armistice Capital LLC (the investor, “Armistice”) provided a notice to the Company in connection with its exercise of its pre-funded warrants to purchase 1,450,000 ADSs (represented by 261,000,000 Ordinary Shares underlying the pre-funded warrants). Following this exercise, there remained 757,000 exercisable pre-funded ADS warrants. The underlying pre-funded ADS warrants were previously registered for resale on Form F-1 with the SEC. On October 25, 2024. Armistice provided notice to the Company in connection with its exercise of its pre-funded warrants to purchase 757,000 ADSs (represented by 136,260,000 Ordinary Shares underlying the warrant). Following this exercise, there remains no exercisable pre-funded ADS warrants related to the Offering. The underlying pre-funded ADS warrants were previously registered for resale on Form F-1 with the SEC. The Company plans to file a resale registration statement on Form S-3 for purposes of covering the resale, if any, of the cash exercise warrants issued in the private placement. No cash warrants have been exercised to date. During October 2024, Carina Biotech (“Carina”) made a milestone payment to the Company in the gross amount of A$ 1,000,000 under the terms of the November 2020 agreement we had entered into with them whereby we had exclusively licensed BNC101 to Carina for the development of CAR-T therapeutics, in return for milestones and royalties or a percentage of the out-licensed revenues. As a result of the acquisition of Eclipse Therapeutic, Inc (“Eclipse”) during the year ended June 30, 2013, the Company is obligated to remit to Eclipse 20 % of the proceeds received from Carina, or A$ 200,000 , in compliance with the merger agreement. There are no other matters or circumstances that have arisen since the end of the financial year which significantly affect or may significantly affect the results of the operations of the Group.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended
	Sep. 30, 2024
Summary of Significant Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosure of revenue, expenses, and certain assets and liabilities at the balance sheet date. Such estimates include the performance obligations under the Company’s collaboration agreements, the collectability of receivables, impairment evaluation for goodwill and intangible assets, and the fair values of contingent consideration and warrants. Actual results may differ from such estimates.

The Company and Basis of Pres_2

The Company and Basis of Presentation (Tables)	3 Months Ended
	Sep. 30, 2024
The Company and Basis of Presentation [Abstract]
Schedule of Company’s Entity Structure at the End of the Reporting Period	Details of the Company’s entity structure at the end of the reporting period are as follows: Name Entity Country of Incorporation Bionomics Limited Parent Australia Bionomics, Inc. Subsidiary United States

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	3 Months Ended
	Sep. 30, 2024
Fair Value Measurements [Line Items]
Schedule of Company’S Liabilities at Fair Value on a Recurring Basis	The following tables set forth the fair value of the Company’s liabilities at fair value on a recurring basis based on the three-tier fair value hierarchy: September 30, 2024 Level 1 Level 2 Level 3 Total Liabilities: Contingent consideration $ - $ - $ 679,313 $ 679,313 Accompanying warrants liability - - 1,691,587 1,691,587 Total liabilities measured at fair value $ - $ - $ 2,370,900 $ 2,370,900 June 30, 2024 Level 1 Level 2 Level 3 Total Liabilities: Contingent consideration $ - $ - $ 587,762 $ 587,762 Accompanying warrants liability - - 4,657,832 4,657,832 Total liabilities measured at fair value $ - $ - $ 5,245,594 $ 5,245,594
Warrant [Member]
Fair Value Measurements [Line Items]
Schedule of Fair Value was Determined by Level 3 Inputs	The following table summarizes changes in the fair value of the contingent consideration and the accompanying warrants liability, each for which each fair value was determined by Level 3 inputs: Contingent Freestanding Balance at June 30, 2024 $ 587,762 $ 4,657,832 Change in fair value 91,551 ( 2,966,245 ) Balance at September 30, 2024 $ 679,313 $ 1,691,587 Contingent Balance at June 30, 2023 $ 2,456,199 Change in fair value ( 124,558 ) Balance at September 30, 2023 $ 2,331,641

Accounts Receivable, Non-trade

Accounts Receivable, Non-trade (Tables)	3 Months Ended
	Sep. 30, 2024
Accounts Receivable, Non-trade [Abstract]
Schedule of Accounts Receivable, Non-Trade	Accounts receivable, non-trade consist of the following: September 30, June 30, 2024 2024 Research and development incentives receivable $ 100,625 $ 96,154 GST receivables 14,059 30,444 Interest receivable 1,276 286 Total accounts receivable, non-trade $ 115,960 $ 126,884

Leases (Tables)

Leases (Tables)	3 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Schedule of Operating and Finance Lease Including the Remaining Lease payments Through the end of the Expected Lease Term	The following table summarizes the Company’s recognition of the Greenhill Lease including the remaining lease payments through the end of the expected lease term: September 30, 2024 Remainder of 2025 $ 145,186 2026 182,584 Remaining lease payments 327,770 Less: effect of discounting ( 108,420 ) Present value of lease liability $ 219,350 Current operating lease liabilities $ 129,881 Non-current operating lease liabilities 89,469 Total $ 219,350
Schedule of Effect of Lease Costs in our Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)	The following table summarizes the effect of lease costs in the Company’s condensed consolidated statements of operations and other comprehensive income (loss): Three months ended September 30, 2024 2023 Operating lease costs Research and development $ 14,313 $ 13,996 General and administrative 16,121 15,724 Total $ 30,434 $ 29,720

Goodwill (Tables)

Goodwill (Tables)	3 Months Ended
	Sep. 30, 2024
Goodwill [Abstract]
Schedule of Carrying Value of Goodwill	The following table summarizes changes in the carrying value of goodwill for the three months ended September 30, 2024 and 2023: Carrying amount at June 30, 2024 $ 8,690,018 Foreign currency exchange differences 213,970 Carrying amount at September 30, 2024 $ 8,903,988 Carrying amount at June 30, 2023 $ 8,694,186 Foreign currency exchange differences ( 119,490 ) Carrying amount at September 30, 2023 $ 8,574,696

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Sep. 30, 2024
Intangible Assets [Abstract]
Schedule of Intellectual Property Capitalized	The acquired intellectual property relates to cancer stem cell technology, and is carried at its cost as at its date of acquisition, less accumulated amortization. Cancer Stem Carrying amount at June 30, 2024 $ 5,467,522 Amortization expense ( 165,683 ) Carrying amount at September 30, 2024 $ 5,301,839 Carrying amount at June 30, 2023 $ 6,130,253 Amortization expense ( 165,683 ) Carrying amount at September 30, 2023 $ 5,964,570

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Sep. 30, 2024
Accrued Expenses and Other Current Liabilities [Abstract]
Schedule of Accrued Expenses	Accrued expenses and other current liabilities consist of the following: September 30, June 30, 2024 2024 Salary and benefits $ 719,235 $ 648,858 Insurance 78,649 311,172 Professional and consulting fees 229,988 297,780 Research and development expenses - 134,910 EDA Loan 34,660 33,120 Other 33,306 37,581 Total accrued expenses and other current liabilities $ 1,095,838 $ 1,463,421

Share Based Compensation (Table

Share Based Compensation (Tables)	3 Months Ended
	Sep. 30, 2024
Share Based Compensation [Abstract]
Schedule of Summarizes Employee and Non-Employee Stock Option Activity	The following table summarizes employee and non-employee share option activity for the three months ended September 30, 2024: Number Weighted Weighted Aggregate (in years) Outstanding as of June 30, 2024 110,449,330 A$ 0.12 4.18 - Lapsed ( 13,015,000 ) A$ 0.01 Outstanding as of September 30, 2024 97,434,330 A$ 0.13 4.74 - Options exercisable as of September 30, 2024 79,909,138 A$ 0.16 5.29 -

Warrants (Tables)

Warrants (Tables)	3 Months Ended
	Sep. 30, 2024
Warrants [Abstract]
Schedule of Warrant Activity	The following table summarizes warrant activity for the three months ended September 30, 2024: Number of (1) Weighted Balance at June 30, 2024 18,932,477 $ 0.66 Exercised ( 4,072,905 ) $ - Balance at September 30, 2024 14,859,572 $ 0.84 (1) Each ADS warrant converts into ordinary shares at a conversion ratio of 1:180 .
Schedule of Classification, Expiration Date, and Exercise Price of Individual Warrants	The classification, expiration date, and exercise price of individual warrants at September 30, 2024 are as follows: Number of Exercise Price Expiration Date Classification 2024 pre-funded ADS warrants 2,207,000 $ 0.0001 No expiry Equity 2024 accompanying ADS warrants 12,652,572 $ 0.99 June 2029 Liability 14,859,572

Loss per Share (Tables)

Loss per Share (Tables)	3 Months Ended
	Sep. 30, 2024
Loss per Share [Abstract]
Schedule of Potential Ordinary Shares	The following potential ordinary shares are anti-dilutive and are therefore excluded from the weighted average number of ordinary shares for the purposes of diluted loss per share. September 30, 2024 2023 Options to purchase common stock 97,434,330 117,196,315 Warrants to purchase common stock 14,859,572 —

The Company and Basis of Pres_3

The Company and Basis of Presentation (Details) - USD ($)	3 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024
The Company and Basis of Presentation [Abstract]
Working capital	$ 5,900,000
Accumulated deficit	(178,781,858)		$ (177,977,071)
Cash and cash equivalents	8,082,410	$ 8,135,059	12,608,109
Net losses	(804,787)	(5,472,568)	$ (15,500,000)
Cash for operating activities	$ (4,433,063)	$ (4,429,800)

The Company and Basis of Pres_4

The Company and Basis of Presentation (Details) - Schedule of Company’s Entity Structure at the End of the Reporting Period	3 Months Ended
	Sep. 30, 2024
Bionomics Limited [Member]
Schedule of Company's Entity Structure at the End of the Reporting Period [Line Items]
Entity	Parent
Country of Incorporation	Australia
Bionomics, Inc. [Member]
Schedule of Company's Entity Structure at the End of the Reporting Period [Line Items]
Entity	Subsidiary
Country of Incorporation	United States

Fair Value Measurement (Details

Fair Value Measurement (Details) - Schedule of Company’s Liabilities at Fair Value on a Recurring Basis - USD ($)	Sep. 30, 2024	Jun. 30, 2024
Liabilities:
Accompanying warrants liability	$ 1,691,587	$ 4,657,832
Fair Value, Recurring [Member]
Liabilities:
Contingent consideration	679,313	587,762
Accompanying warrants liability	1,691,587	4,657,832
Total liabilities measured at fair value	2,370,900	5,245,594
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Liabilities:
Contingent consideration
Accompanying warrants liability
Total liabilities measured at fair value
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Liabilities:
Contingent consideration
Accompanying warrants liability
Total liabilities measured at fair value
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Liabilities:
Contingent consideration	679,313	587,762
Accompanying warrants liability	1,691,587	4,657,832
Total liabilities measured at fair value	$ 2,370,900	$ 5,245,594

Fair Value Measurement (Detai_2

Fair Value Measurement (Details) - Schedule of Fair Value was Determined by Level 3 Inputs - USD ($)	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Contingent Consideration in a Business Combination [Member]
Schedule of Fair Value was Determined by Level 3 Inputs [Line Items]
Balance at beginning	$ 587,762	$ 2,456,199
Change in fair value	91,551	(124,558)
Balance at ending	679,313	$ 2,331,641
Freestanding Financial Instruments Accompanying Warrant Liability [Member]
Schedule of Fair Value was Determined by Level 3 Inputs [Line Items]
Balance at beginning	4,657,832
Change in fair value	(2,966,245)
Balance at ending	$ 1,691,587

Accounts Receivable, Non-trad_2

Accounts Receivable, Non-trade (Details) - Schedule of Accounts Receivable, Non-Trade - USD ($)	Sep. 30, 2024	Jun. 30, 2024
Schedule of Accounts Receivable, Non-Trade [Abstract]
Research and development incentives receivable	$ 100,625	$ 96,154
GST receivables	14,059	30,444
Interest receivable	1,276	286
Total accounts receivable, non-trade	$ 115,960	$ 126,884

Leases (Details)

Leases (Details)	3 Months Ended
	Sep. 30, 2024	Jun. 30, 2021
Leases [Abstract]
Lease term		5 years
Lease payments percentage	3%
Renew or extend term	1 year
Weighted average remaining lease percentage	3.50%
Weighted average remaining lease term	1 year 9 months 18 days

Leases (Details) - Schedule of

Leases (Details) - Schedule of Operating and Finance Lease Including the Remaining Lease payments Through the end of the Expected Lease Term - USD ($)	Sep. 30, 2024	Jun. 30, 2024
Schedule of Operating and Finance Leases [Abstract]
Remainder of 2025	$ 145,186
2026	182,584
Remaining lease payments	327,770
Less: effect of discounting	(108,420)
Present value of operating lease liability	219,350
Current operating lease liabilities	129,881	$ 121,990
Non-current operating lease liabilities	$ 89,469	$ 117,628

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of Effect of Lease Costs in our Condensed Consolidated Statements of Operations and Comprehensive (Income) Loss - USD ($)	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Operating lease costs
Research and development	$ 14,313	$ 13,996
General and administrative	16,121	15,724
Total	$ 30,434	$ 29,720

Goodwill (Details) - Schedule o

Goodwill (Details) - Schedule of Carrying Value of Goodwill - USD ($)	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Schedule of Carrying Value of Goodwill [Abstract]
Carrying amount, Beginning	$ 8,690,018	$ 8,694,186
Foreign currency exchange differences	213,970	(119,490)
Carrying amount, Ending	$ 8,903,988	$ 8,574,696

Intangible Assets (Details) - S

Intangible Assets (Details) - Schedule of Intellectual Property Capitalized - USD ($)	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Schedule of Intellectual Property Capitalized [Line Items]
Carrying amount, Balance	$ 5,467,522
Carrying amount, Balance	5,301,839
Cancer Stem Cell Technology [Member]
Schedule of Intellectual Property Capitalized [Line Items]
Carrying amount, Balance	5,467,522	$ 6,130,253
Amortization expense	(165,683)	(165,683)
Carrying amount, Balance	$ 5,301,839	$ 5,964,570

Intangible Assets (Details)

Intangible Assets (Details)	Sep. 30, 2024
Intangible Assets [Abstract]
Estimated useful	20 years

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - Schedule of Accrued Expenses - USD ($)	Sep. 30, 2024	Jun. 30, 2024
Schedule of Accrued Expenses [Abstract]
Salary and benefits	$ 719,235	$ 648,858
Insurance	78,649	311,172
Professional and consulting fees	229,988	297,780
Research and development expenses	0	134,910
EDA Loan	34,660	33,120
Other	33,306	37,581
Total accrued expenses and other current liabilities	$ 1,095,838	$ 1,463,421

Share Based Compensation (Detai

Share Based Compensation (Details) $ in Millions	3 Months Ended
	Sep. 30, 2024 AUD ($) shares	Sep. 30, 2024 USD ($) shares	Sep. 30, 2023 USD ($) shares	Sep. 30, 2024 USD ($)
Share Based Compensation [Line Items]
Employee share plan	$ 1,000
Vesting period	5 years	5 years
Weighted average period	1 year 2 months 12 days	1 year 2 months 12 days
Equity awards issued during period | shares	0	0	0
Employee Share A Plan [Member]
Share Based Compensation [Line Items]
Employee share plan	$ 1,000
Employee Share Plan [Member]
Share Based Compensation [Line Items]
Employee share plan	1,000
Annual allocation	$ 1,000
Share issued (in Shares) | shares
Maximum [Member]
Share Based Compensation [Line Items]
Unrecognized compensation cost (in Dollars)				$ 0.1
Recognized total stock-based compensation expense (in Dollars)		$ 0.1	$ 0.1

Share Based Compensation (Det_2

Share Based Compensation (Details) - Schedule of Summarizes Employee and Non-Employee Stock Option Activity	3 Months Ended		12 Months Ended
	Sep. 30, 2024 USD ($) shares	Sep. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) shares	Sep. 30, 2024 $ / shares
Schedule of Summarizes Employee and Non-Employee Stock Option Activity [Line Items]
Number of Options, Outstanding Beginning Balance | shares	110,449,330
Weighted Average Exercise Price per Share, Outstanding Beginning Balance | $ / shares		$ 0.12
Weighted Average Remaining Contractual Term, Outstanding Ending Balance	4 years 8 months 26 days		4 years 2 months 4 days
Aggregate Intrinsic Value, Outstanding Ending Balance | $
Number of Options, Lapsed | shares	(13,015,000)
Weighted Average Exercise Price per Share, Lapsed | $ / shares		0.01
Number of Options, Outstanding Ending Balance | shares	97,434,330		110,449,330
Weighted Average Exercise Price per Share, Outstanding Ending Balance | $ / shares		$ 0.13
Number of Options, Options exercisable | shares	79,909,138	79,909,138
Weighted Average Exercise Price per Share, Options exercisable | $ / shares				$ 0.16
Weighted Average Remaining Contractual Term, Options exercisable	5 years 3 months 14 days
Aggregate Intrinsic Value, Options exercisable | $

Warrants (Details)

Warrants (Details) - ADS [Member]	3 Months Ended
	Sep. 30, 2024 shares
Warrants [Line Items]
Conversion ratio	1:180
Warrant [Member]
Warrants [Line Items]
Vested and exercisable	14,859,572
weighted average remaining contractual life	4 years 8 months 4 days

Warrants (Details) - Schedule o

Warrants (Details) - Schedule of Warrant Activity - ADS Warrants [Member]	3 Months Ended
	Sep. 30, 2024 $ / shares shares
Schedule of Warrant Activity [Line Items]
Number of ADS Warrants, Beginning Balance | shares	18,932,477	[1]
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 0.66
Number of ADS Warrants, Exercised | shares	(4,072,905)	[1]
Weighted Average Exercise Price, Exercised | $ / shares
Number of ADS Warrants, Ending Balance | shares	14,859,572	[1]
Weighted Average Exercise Price, Ending Balance | $ / shares	$ 0.84
[1] Each ADS warrant converts into ordinary shares at a conversion ratio of 1:180 .

Warrants (Details) - Schedule_2

Warrants (Details) - Schedule of Classification, Expiration Date, and Exercise Price of Individual Warrants	3 Months Ended
	Sep. 30, 2024 $ / shares shares
2024 pre-funded ADS warrants [Member]
Schedule of Classification, Expiration Date, and Exercise Price of Individual Warrants [Line Items]
Number of ADS Warrants Outstanding | shares	2,207,000
Exercise Price | $ / shares	$ 0.0001
Expiration Date	No expiry
Classification	Equity
2024 accompanying ADS warrants [Member]
Schedule of Classification, Expiration Date, and Exercise Price of Individual Warrants [Line Items]
Number of ADS Warrants Outstanding | shares	12,652,572
Exercise Price | $ / shares	$ 0.99
Expiration Date	June 2029
Classification	Liability

Ordinary Shares (Details)

Ordinary Shares (Details) - USD ($)		3 Months Ended
	Oct. 03, 2023	Sep. 30, 2024	Sep. 30, 2023
Class of Stock [Line Items]
Issuance of shares, net of issuance costs			$ 612,538
Stock issuance costs		$ 227,747	$ 500,000
Ordinary Shares
Class of Stock [Line Items]
Stock issued during period, shares			378,155,880
American Depositary Shares
Class of Stock [Line Items]
Stock issued during period, shares	1,508,727		2,100,866
Issuance of shares, net of issuance costs	$ 5,600,000		$ 67,000,000
Stock issuance costs			$ 500,000

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Income Taxes [Abstract]
Effective income tax rate	14.10%	0.60%
Income tax benefit	$ 132,187	$ 34,793

Loss per Share (Details) - Sche

Loss per Share (Details) - Schedule of Potential Ordinary Shares - shares	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Options to Purchase Common Stock [Member]
Schedule of Potential Ordinary Shares [Line Items]
Potential ordinary shares are anti-dilutive	97,434,330	117,196,315
Warrants To Purchase Common Stock [Member]
Schedule of Potential Ordinary Shares [Line Items]
Potential ordinary shares are anti-dilutive	14,859,572

Related Party Transactions (Det

Related Party Transactions (Details)	3 Months Ended
	Sep. 30, 2024 USD ($)
Related Party Transactions [Line Items]
Monthly fee	$ 15,000
Fundraising proceeds percentage	5%
WG Partners LLP [Member]
Related Party Transactions [Line Items]
Service paid	$ 59,841

Contingent Consideration (Detai

Contingent Consideration (Details) $ in Millions	Sep. 30, 2024 USD ($)
Contingent Consideration [Abstract]
liability	$ 0.1

Commitments and Contingencies (

Commitments and Contingencies (Details)	3 Months Ended
	Sep. 30, 2024 USD ($)
Dr. Spyros Papapetropoulos [Member]
Contingencies [Line Items]
Severance pay	$ 787,500

Subsequent Events (Details)

Subsequent Events (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2013	Oct. 31, 2024	Oct. 25, 2024	Oct. 24, 2024
Eclipse
Subsequent Events [Line Items]
Business acquisition obligation percentage	20%
Business acquisition obligation amount	$ 200,000
Subsequent Event [Member]
Subsequent Events [Line Items]
Number of warrants to be issued (in Shares)			136,260,000	261,000,000
Warrant exercisable				757,000
Milestone payment		$ 1,000,000
Subsequent Event [Member] | Prefunded ADS [Member]
Subsequent Events [Line Items]
Number of warrants to be issued (in Shares)			757,000	1,450,000
Cash warrant exercised			0